Cargando…

Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis

OBJECTIVES: A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam, investigating which approach is better and worthy of recommendation for clinical use. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Zhang, Chao, Zhou, Quanyu, Wang, Yike, Chen, Lujia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289069/
https://www.ncbi.nlm.nih.gov/pubmed/25575030
http://dx.doi.org/10.1371/journal.pone.0116769
_version_ 1782352050904891392
author Yang, Hui
Zhang, Chao
Zhou, Quanyu
Wang, Yike
Chen, Lujia
author_facet Yang, Hui
Zhang, Chao
Zhou, Quanyu
Wang, Yike
Chen, Lujia
author_sort Yang, Hui
collection PubMed
description OBJECTIVES: A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam, investigating which approach is better and worthy of recommendation for clinical use. METHODS: Articles were gathered from PubMed, Web of Science, ProQuest, Science Direct, Cochrane, two Chinese literature databases (CNKI, Wan Fang Data) and related ICAAC and ACCP conferences. Randomized controlled and observational studies that compared extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam were identified from the databases above and analyzed. Two reviewers independently extracted and investigated the data. A meta-analysis was performed using Revman 5.2 software. The quality of each study was assessed. Sensitivity analysis and publication bias were evaluated. RESULTS: Five randomized controlled trials and nine observational studies were included in this study. All included studies had high quality and no publication bias was found. Compared to the conventional intermittent infusion approach, the extended or continuous infusion group had a significantly higher clinical cure rate (OR 1.88, 95% CI 1.29-2.73, P = 0.0009) and a lower mortality rate (OR 0.67, 95% CI 0.50-0.89, P = 0.005). No statistical difference was observed for bacteriologic cure (OR 1.40, 95% CI 0.82-2.37, P = 0.22) between the two dosing regimens. The sensitivity analysis showed the results were stable. CONCLUSIONS: Our systematic review and meta-analysis suggested that the extended or continuous infusion strategy of piperacillin/tazobactam should be recommended for clinical use considering its higher clinical cure rate and lower mortality rate in comparison with conventional intermittent strategy. Data from this study could be extrapolated for other β-lactam antimicrobials. Therefore, this dosing strategy could be considered in clinical practice.
format Online
Article
Text
id pubmed-4289069
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42890692015-01-12 Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis Yang, Hui Zhang, Chao Zhou, Quanyu Wang, Yike Chen, Lujia PLoS One Research Article OBJECTIVES: A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam, investigating which approach is better and worthy of recommendation for clinical use. METHODS: Articles were gathered from PubMed, Web of Science, ProQuest, Science Direct, Cochrane, two Chinese literature databases (CNKI, Wan Fang Data) and related ICAAC and ACCP conferences. Randomized controlled and observational studies that compared extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam were identified from the databases above and analyzed. Two reviewers independently extracted and investigated the data. A meta-analysis was performed using Revman 5.2 software. The quality of each study was assessed. Sensitivity analysis and publication bias were evaluated. RESULTS: Five randomized controlled trials and nine observational studies were included in this study. All included studies had high quality and no publication bias was found. Compared to the conventional intermittent infusion approach, the extended or continuous infusion group had a significantly higher clinical cure rate (OR 1.88, 95% CI 1.29-2.73, P = 0.0009) and a lower mortality rate (OR 0.67, 95% CI 0.50-0.89, P = 0.005). No statistical difference was observed for bacteriologic cure (OR 1.40, 95% CI 0.82-2.37, P = 0.22) between the two dosing regimens. The sensitivity analysis showed the results were stable. CONCLUSIONS: Our systematic review and meta-analysis suggested that the extended or continuous infusion strategy of piperacillin/tazobactam should be recommended for clinical use considering its higher clinical cure rate and lower mortality rate in comparison with conventional intermittent strategy. Data from this study could be extrapolated for other β-lactam antimicrobials. Therefore, this dosing strategy could be considered in clinical practice. Public Library of Science 2015-01-09 /pmc/articles/PMC4289069/ /pubmed/25575030 http://dx.doi.org/10.1371/journal.pone.0116769 Text en © 2015 Yang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Yang, Hui
Zhang, Chao
Zhou, Quanyu
Wang, Yike
Chen, Lujia
Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title_full Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title_fullStr Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title_full_unstemmed Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title_short Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
title_sort clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289069/
https://www.ncbi.nlm.nih.gov/pubmed/25575030
http://dx.doi.org/10.1371/journal.pone.0116769
work_keys_str_mv AT yanghui clinicaloutcomeswithalternativedosingstrategiesforpiperacillintazobactamasystematicreviewandmetaanalysis
AT zhangchao clinicaloutcomeswithalternativedosingstrategiesforpiperacillintazobactamasystematicreviewandmetaanalysis
AT zhouquanyu clinicaloutcomeswithalternativedosingstrategiesforpiperacillintazobactamasystematicreviewandmetaanalysis
AT wangyike clinicaloutcomeswithalternativedosingstrategiesforpiperacillintazobactamasystematicreviewandmetaanalysis
AT chenlujia clinicaloutcomeswithalternativedosingstrategiesforpiperacillintazobactamasystematicreviewandmetaanalysis